Welcome to NewPressRelease.com a free press release service. Publishing press releases for Public Relations never been easier. Just register (it's free and it takes less then a 1 minute) then use Submit Press Release. Our services aim to help you reach journalists and to improve visibility in search engine listings, so you can get the most publicity possible.

Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation

Health and Fitness

(Free Press Release) Bharatbook.com announces a new report on Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation. The report help to Understanding of the focal shifts in molecular targets in the psoriasis pipeline, Understanding of the distribution of pipeline programs by phase of development, molecule type and molecular target, Scientific and clinical analysis of first-in-class developmental programs.

Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation


      

(NewPressRelease.com - free press release distribution)

July. 09, 2014 : Bharat Book Bureau presents the new report, on "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation". This report also help to Assessment of the valuations of licensed and co-developed psoriasis treatments, A list of the first-in-class therapies potentially open to deal-making opportunities, & Analysis of financial valuations on licensed or co-developed first-in-class therapies and generics.

“Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation”, which identifies and assesses first-in-class innovation in the psoriasis development pipeline. Over the last decade, a greater understanding of the underlying pathophysiology of psoriasis has increased emphasis on developing immuneomodulating therapies, as opposed to largely symptomatic treatments. This is currently reflected in a competitive market dominated by multiple disease-modifying biologic therapies (inhibitors of TNF-a and IL-12/IL-23) and generic small-molecule therapies. Despite this, there are significant unmet needs in the market, including safety concerns regarding immunomodulation. This is a particularly important issue for the long-term commercial and clinical success of psoriatic therapeutics, especially for emerging biologics. Another unmet need is ease of drug application, as biologic drug delivery is invasive and painful. This allows for pipeline programs that offer a more refined approach to immunomodulation and ease of drug application to gain market share upon entry. In a pipeline of over 200 programs, approximately one third exhibits a novel mechanism of action. Innovative programs target a wide range of molecules implicated in immune signaling, such as cytokines and B and T cell antigens. Several promising first-in-class therapies can selectively modulate specific subsets of immune cells without compromising the entire immune system.

In particular, biologics that target a subset of T cells, which are strongly implicated in autoimmune pathophysiology, could allow for specificity of immune suppression and thereby reduce adverse side effects. Based on clinical trials, IL-17-targeted therapies have demonstrated superiority over currently established therapies in achieving advanced clinical endpoints. Other agents which activate regulatory arms of the immune system have also shown promising clinical profiles. In addition, innovative programs that target molecules have only recently gained recognition of their therapeutic value in the treatment of psoriasis, including novel angiogenic proteins, signaling transduction proteins and novel nuclear receptors. Despite their recent implication in disease pathophysiology, many of these agents have also demonstrated clinical utility in the treatment of psoriasis and are likely to contribute to a diversified therapeutic landscape.

Table of Contents:


1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 The Case for Innovation
2.1 Growing Opportunities for Biologic Products
2.2 Diversification of Molecular Targets
2.3 Innovative First-in-Class Product Developments Remain Attractive
2.4 Changes in the Clinical and Commercial Environment Will be More Favorable to Products That Target Niche Indications and Patient Populations
2.5 Innovation in Psoriasis

3 Clinical and Commercial Landscape
3.1 Disease Introduction
3.2 Epidemiology
3.3 Etiology
3.3.1 Genetic Predisposition
3.3.2 Environmental Factors
3.4 Pathophysiology
3.4.1 Keratinocytes
3.4.2 Dendritic Cells
3.4.3 T-Cells
3.4.4 Angiogenesis
3.4.5 Growth Factors
3.5 Symptoms and Co-morbidities
3.5.1 Skin Manifestations
3.5.2 Psoriatic Arthritis
3.5.3 Uveitis
3.5.4 Cardiovascular Disease
3.5.5 Psychological Impact
3.6 Diagnosis of Psoriasis
3.6.1 Diagnosis of Psoriatic Arthritis
3.7 Treatment
3.7.1 Pharmacological Therapies
3.7.2 Topical Medications
3.7.3 Systemic Medications
3.7.4 Non-Pharmacological Therapies
3.7.5 Combination and Rotational Therapies
3.8 Overview of Marketed Products for Psoriasis
3.8.1 Oral Non-Biologic DMARDs
3.8.2 Off-Label Non-Biologic DMARDs
3.8.3 Biologics
3.8.4 Comparative Efficacy and Safety of Marketed Products
3.8.5 Unmet Need

For more information kindly visit :https://www.bharatbook.com/healthcare-market-research-reports-505946/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation.html

Related Reports :https://www.bharatbook.com/market-research-report/healthcare.html

About Bharat Book Bureau:

Bharat Book Bureau
is the leading market research information provider for market research reports, company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don’t match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

OR

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
For live chat : http://bit.ly/19m3TU4
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Website: www.bharatbook.com
Follow us on twitter: https://twitter.com/researchbook
Follow us on linkedin : http://www.linkedin.com/company/bharat-book-bureau
Our Blog : http://blog.bharatbook.com/

 




Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation

Source: Press Release

---------------------------

Disclaimer

If you have any questions regarding information in this press release, please contact the person listed as the Author or use the contact informations published in the press release. Please do not attempt to contact NewPressRelease.com. We are unable to assist you with any information regarding this release. NewPressRelease.com disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.

Related Items

All press release information on this site, including free press releases, is solely based on what our users submit. NewPressRelease.com disclaims that any right and responsibility for the information goes to the user who submit the press release. Some press release may be confusing without additional explanation. You should contact the provider with any questions about the information presented. In case some press release damages your benefits or violate your rights in any way, please contact us and we'll remove it immediately.


Copyright © 2008 - 2018 Free Press Release by NewPressRelease.com